Wednesday, July 29, 2020

Roche#39;s Tocilizumab fails to meet primary end points for COVID-19 associated pneumonia

Roche#39;s Tocilizumab fails to meet primary end points for COVID-19 associated pneumonia However, Roche said there was a positive trend in time to hospital discharge in patients treated with Actemra. The median time to discharge or ‘ready to discharge’ for Actemra was 20 days and for placebo was 28 days.

from Moneycontrol Business News https://ift.tt/334PmjR
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Oil Price Today (March 25): Oil slips below $100 on rising hopes of Iran war ceasefire. Here’s what experts are saying

Oil prices saw a significant drop as hopes for a ceasefire in the Middle East grew. Reports suggested a U.S. proposal aimed at ending the co...